- Home
- TLRY vs SVRA Comparison
TLRY vs SVRA Comparison
Compare TLRY & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | SVRA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.2M | 1.1B |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | TLRY | SVRA |
|---|---|---|
| Price | $6.30 | $5.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $103.33 | $7.33 |
| AVG Volume (30 Days) | ★ 2.2M | 1.4M |
| Earning Date | 04-01-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.17 | $430.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.89 |
| 52 Week High | $15.70 | $7.01 |
Technical Indicators
Market Signals| Indicator | TLRY | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 44.30 |
| Support Level | $1.00 | $5.10 |
| Resistance Level | $8.20 | $6.10 |
| Average True Range (ATR) | 0.32 | 0.27 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 13.04 | 35.32 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).